drugset / Trial / NCT04244825
Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis
Timeline
- Start
- 2019-12-15
- Primary completion
- 2020-09-14
- Completion
- 2020-11-05
Outcome
Outcome not reported
Stopped: “Withdrawn due to concerns for patient safety during COVID-19 crisis”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DAZCAPISTAT | Small molecule | 300 mg | Oral |
| Subject | DAZCAPISTAT | Small molecule | 600 mg | Oral |
| Subject | DAZCAPISTAT | Small molecule | 900 mg | Oral |